Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

15.81 -1.18 (-6.95%)
Streaming Delayed Price Updated: 10:09 AM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novocure Ltd Ord Sh

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
3 Healthcare Stocks That Could Be Turkeys in November
You might want to avoid stuffing your portfolio with them. 
Via The Motley Fool
NovoCure (NVCR) Q3 2021 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
No Negative Reaction
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today. 
Via Talk Markets
Why NovoCure Stock Is Sinking This Week
Investors weren't happy with the company's Q3 update. 
Via The Motley Fool
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Recap: NovoCure Q3 Earnings
NovoCure (NASDAQ:NVCR) reported its Q3 earnings results on Thursday, October 28, 2021 at 06:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
From Novocure
Via Business Wire
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
From Novocure
Via Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Bitcoin Futures Arrive
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
More Chinese Trouble
A day after the consumer price rise there was another price rise for producer markets. 
Via Talk Markets
This Unstoppable Cancer-Treatment Company's Stock Is on Sale Now
Novocure's stock keeps sliding, but the company continues to perform. 
Via The Motley Fool
This Company's Device is Becoming Essential to Cancer Treatment -- Why Is the Stock Slumping?
Is it time to buy this stock nearly at its 52 week low? 
Via The Motley Fool
Cramer Likes Ford, But Suggests Waiting For Dips To Buy These Stocks
On Friday's "Mad Money Lightning ... 
Via Benzinga
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
From Novocure
Via Business Wire
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
Novocure to Report Third Quarter 2021 Financial Results
From Novocure
Via Business Wire
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating... 
Via Benzinga
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
From Novocure
Via Business Wire
Pressure Day
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
A Weak Week
Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants. 
Via Talk Markets
Delta Variant Fears Continue
The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher. 
Via Talk Markets
This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?
Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster. 
Via The Motley Fool
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
From Novocure
Via Business Wire
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
From Novocure
Via Business Wire
Novocure Appoints Bill Burke as Chief Human Resources Officer
From Novocure
Via Business Wire
Friday the Thirteenth
The stock week in points eastward was mixed. The USA markets face a bear correction. 
Via Talk Markets
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.